基质金属蛋白酶
骨关节炎
软骨
细胞外基质
体外
自愈水凝胶
肿瘤坏死因子α
软骨寡聚基质蛋白
II型胶原
药理学
细胞因子
医学
化学
癌症研究
免疫学
病理
生物化学
内科学
解剖
有机化学
替代医学
作者
Qichan Hu,Steven L. Williams,Alessandra Palladino,Melanie Ecker
出处
期刊:Polymers
[Multidisciplinary Digital Publishing Institute]
日期:2024-06-01
卷期号:16 (11): 1572-1572
被引量:7
标识
DOI:10.3390/polym16111572
摘要
Osteoarthritis (OA) is a chronic joint disease characterized by irreversible cartilage degradation. Current clinical treatment options lack effective pharmaceutical interventions targeting the disease's root causes. MMP (matrix metalloproteinase) inhibitors represent a new approach to slowing OA progression by addressing cartilage degradation mechanisms. However, very few drugs within this class are in preclinical or clinical trial phases. Hydrogel-based 3D in vitro models have shown promise as preclinical testing platforms due to their resemblance to native extracellular matrix (ECM), abundant availability, and ease of use. Metalloproteinase-13 (MMP-13) is thought to be a major contributor to the degradation of articular cartilage in OA by aggressively breaking down type II collagen. This study focused on testing MMP-13 inhibitors using a GelMA-alginate hydrogel-based OA model induced by cytokines interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α). The results demonstrate a significant inhibition of type II collagen breakdown by measuring C2C concentration using ELISA after treatment with MMP-13 inhibitors. However, inconsistencies in human cartilage explant samples led to inconclusive results. Nonetheless, the study highlights the GelMA-alginate hydrogel-based OA model as an alternative to human-sourced cartilage explants for in vitro drug screening.
科研通智能强力驱动
Strongly Powered by AbleSci AI